Chuxiao Shao

Lishui University, People's Liberation Army 401 Hospital

Papers

Total Citations

H-Index

About

Chuxiao Shao is a pioneering researcher in the rapidly evolving field of cancer nanomedicine, with a particular focus on translating fundamental nanocarrier principles into next-generation precision oncology platforms. Their most cited work, a comprehensive 2025 review on recent advances in cancer nanomedicine, traces the field’s evolution from the landmark 1995 approval of Doxil® to today’s programmable, smart-targeting systems. Shao’s analysis highlights a coherent continuum of progress—from passive EPR-mediated tumor accumulation to active ligand-based targeting and personalized therapeutic strategies—providing a critical roadmap for researchers and clinicians alike. This influential review has already garnered 15 citations, underscoring its impact as a go-to resource for understanding the trajectory of nanomedicine. In addition to their foundational work in drug delivery, Shao has contributed to surgical innovation, notably co-authoring a 2021 study on transoral robotic thyroidectomy. This clinical work, based on an initial 30 cases, demonstrated the safety and efficacy of the robotic approach for early thyroid cancers, achieving superior cosmetic outcomes with careful patient selection. By bridging bench-to-bedside advances in nanomedicine with practical surgical techniques, Chuxiao Shao exemplifies the multidisciplinary expertise driving modern oncology.